Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HRD + BRCA1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

HRD + BRCA1 mutation	Ovarian Cancer	HRD + BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA1 mutation	Fallopian Tube Cancer	HRD + BRCA1 mutation	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA1 mutation	Peritoneal Cancer	HRD + BRCA1 mutation	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA1 mutation	Ovarian Cancer	HRD + BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: C2 – Inclusion Criteria niraparib Sensitive : C2	niraparib Sensitive: C2 – Inclusion Criteria niraparib Sensitive : C2
HRD + BRCA1 mutation	Peritoneal Cancer	HRD + BRCA1 mutation	Peritoneal Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
HRD + BRCA1 mutation	Fallopian Tube Cancer	HRD + BRCA1 mutation	Fallopian Tube Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
HRD + BRCA1 mutation	Endometrial Cancer	HRD + BRCA1 mutation	Endometrial Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3